Efficacy of rituximab in anti‐myelin‐associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow‐up

BACKGROUND AND PURPOSE: We evaluated the clinical and neurophysiological efficacy of rituximab (RTX) in a neurophysiologically homogeneous group of patients with monoclonal gammopathy and immunoglobulin M (IgM) anti‐myelin‐associated glycoprotein antibody (anti‐MAG) demyelinating polyneuropathy. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Parisi, Mattia, Dogliotti, Irene, Clerico, Michele, Bertuzzo, Davide, Benevolo, Giulia, Orsucci, Lorella, Schiavetti, Irene, Cavallo, Roberto, Cavallo, Federica, Ragaini, Simone, Di Liberto, Alessandra, Ferrante, Martina, Bondielli, Giulia, Artusi, Carlo Alberto, Drandi, Daniela, Lopiano, Leonardo, Ferrero, Bruno, Ferrero, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Stroke
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825860/
https://www.ncbi.nlm.nih.gov/pubmed/36083713
http://dx.doi.org/10.1111/ene.15553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825860/
https://www.ncbi.nlm.nih.gov/pubmed/36083713
http://dx.doi.org/10.1111/ene.15553

Ejemplares similares